share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰製藥 | 144:擬議出售證券

美股sec公告 ·  02/21 23:46
牛牛AI助理已提取核心訊息
Vertex Pharmaceuticals Inc. officer Ourania Tatsis is set to sell 360 common shares of the company on 02/21/2024, as per the latest filing. The shares, valued at an aggregate market value of $151,837.20, were acquired on 02/20/2024 as performance shares, a form of compensation from the issuer. This transaction follows a recent history of sales by Tatsis, who sold 794 shares over the past three months, generating total gross proceeds of $333,934.56. The planned sale is in line with a notice dated 02/21/2024, with the plan adopted on 05/09/2023.
Vertex Pharmaceuticals Inc. officer Ourania Tatsis is set to sell 360 common shares of the company on 02/21/2024, as per the latest filing. The shares, valued at an aggregate market value of $151,837.20, were acquired on 02/20/2024 as performance shares, a form of compensation from the issuer. This transaction follows a recent history of sales by Tatsis, who sold 794 shares over the past three months, generating total gross proceeds of $333,934.56. The planned sale is in line with a notice dated 02/21/2024, with the plan adopted on 05/09/2023.
最新文件顯示,Vertex Pharmicals Inc.高管歐拉尼亞·塔西斯定於2024年2月21日出售該公司的360股普通股。這些股票的總市值爲151,837.20美元,於2024年2月20日作爲績效股票收購,這是發行人的一種補償。該交易遵循了塔西斯最近的銷售歷史,塔西斯在過去三個月中出售了794股股票,總收益爲333,934.56美元。計劃中的出售與2024年2月21日的通知一致,該計劃於2023年9月5日通過。
最新文件顯示,Vertex Pharmicals Inc.高管歐拉尼亞·塔西斯定於2024年2月21日出售該公司的360股普通股。這些股票的總市值爲151,837.20美元,於2024年2月20日作爲績效股票收購,這是發行人的一種補償。該交易遵循了塔西斯最近的銷售歷史,塔西斯在過去三個月中出售了794股股票,總收益爲333,934.56美元。計劃中的出售與2024年2月21日的通知一致,該計劃於2023年9月5日通過。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。